NASDAQ · JANX
Healthcare · Biotechnology
$17.39
Up+$0.11 (+0.64%)
Updated Aug 22, 2026, 12:48 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
JANX closed at $17.39 after 21 trading sessions, up 13.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $17.40 | $17.6999 | $17.21 | $17.39 | 520.04K |
| Aug 20, 2026 | $17.29 | $17.64 | $17.19 | $17.28 | 1.12M |
| Aug 19, 2026 | $17.21 | $17.72 | $16.96 | $17.52 | 914.23K |
| Aug 18, 2026 | $16.21 | $16.99 | $16.10 | $16.96 | 583.18K |
| Aug 17, 2026 | $16.07 | $16.37 | $15.93 | $16.26 | 540.81K |
| Aug 14, 2026 | $16.00 | $16.22 | $15.71 | $16.12 | 441.53K |
| Aug 13, 2026 | $16.74 | $16.77 | $15.96 | $16.00 | 847.45K |
| Aug 12, 2026 | $16.44 | $16.82 | $16.33 | $16.67 | 652.91K |
| Aug 11, 2026 | $16.41 | $16.835 | $16.21 | $16.52 | 577.86K |
| Aug 10, 2026 | $15.90 | $16.63 | $15.725 | $16.41 | 740.4K |
| Aug 7, 2026 | $15.73 | $16.19 | $15.73 | $15.85 | 689.03K |
| Aug 6, 2026 | $15.99 | $16.39 | $15.93 | $16.10 | 540.89K |
| Aug 5, 2026 | $16.01 | $16.16 | $15.82 | $16.00 | 546.04K |
| Aug 4, 2026 | $15.42 | $15.98 | $15.345 | $15.96 | 564.66K |
| Aug 3, 2026 | $15.24 | $15.49 | $14.86 | $15.32 | 558.94K |
| Jul 31, 2026 | $15.55 | $15.56 | $15.00 | $15.17 | 510.51K |
| Jul 30, 2026 | $14.88 | $15.695 | $14.79 | $15.58 | 690.27K |
| Jul 29, 2026 | $14.92 | $15.23 | $14.60 | $14.96 | 602.87K |
| Jul 28, 2026 | $15.64 | $15.71 | $14.57 | $15.00 | 684.78K |
| Jul 27, 2026 | $15.60 | $15.95 | $15.29 | $15.57 | 1.4M |
| Jul 24, 2026 | $15.81 | $15.8654 | $15.24 | $15.33 | 550.01K |
The latest Smart Investors Daily articles mentioning JANX.
JANX research
Company profile and research snapshot.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Buy | — |
| May 8, 2026 | Piper Sandler | Overweight | — |
| May 8, 2026 | Guggenheim | Buy | — |
| May 8, 2026 | Wedbush | Outperform | — |
| Apr 28, 2026 | Jones Trading | Buy | — |
No generated briefing is available yet.
Benzinga · Feb 27, 2026
Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $150 to $100.
Benzinga · Feb 27, 2026
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $72 to $68.
Benzinga · Feb 26, 2026
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.64) by 20.19 percent. This is a 41.67 percent decrease over losses of $(0.36) per share
SeekingAlpha · Dec 9, 2025
2025-12-09. The following slide deck was published by Janux Therapeutics, Inc.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning JANX.
